AI Analysis | Feedback

1. Regeneron for next-generation antibodies.

2. Moderna, but for advanced antibody drugs instead of mRNA therapeutics.

AI Analysis | Feedback

• ABP-100: An investigational bispecific antibody being developed for the treatment of HER2-positive solid tumors.
• ABP-300: An investigational bispecific antibody designed to target PD-L1 and CD3 for the treatment of various solid tumors.
• Diversimer™ Platform: A proprietary technology platform used for the discovery and development of novel bispecific antibody therapeutics.

AI Analysis | Feedback

Abpro (symbol: ABP) is a clinical-stage biotechnology company focused on developing antibody therapeutics. As such, it primarily sells to other companies (B2B) through collaboration agreements, licensing deals, and partnerships rather than selling products directly to individuals.

Based on Abpro's recent financial filings (Form 10-K for the fiscal year ended December 31, 2023, filed March 2024), its revenue has been derived from collaboration agreements. The company reported that **Astellas Pharma Inc.** was the sole source of its revenue in 2023.

The major customer identified from these filings is:

• Astellas Pharma Inc. (TSE: 4503)

Note: Astellas Pharma Inc. was the sole source of Abpro's collaboration revenue in 2023. While rights to a specific program (ABPR-101) were returned to Abpro by Astellas in April 2023, revenue recognition related to services performed under the agreement continued throughout the fiscal year. Historically, Abpro has also engaged in partnerships with other companies such as NJCTTQ Pharma Co., Ltd. and Shanghai Miracogen Inc. (both private companies), and previously with Global Blood Therapeutics (acquired by Pfizer, NYSE: PFE) and Mersana Therapeutics (NASDAQ: MRSN).

AI Analysis | Feedback

null

AI Analysis | Feedback

Miles Suk, CEO, Chairman

Miles Suk was appointed Chief Executive Officer of Abpro in March 2025 and has served as a member of Abpro's board of directors since January 2020. He co-founded Bio CND Inc., a pharmaceutical company that was later acquired. From September 2011 to September 2019, Mr. Suk served on the board of directors, and as a senior director and advisor, of Gan & Lee Pharmaceuticals Co., Ltd., a public pharmaceutical company. He also possesses extensive experience in licensing, strategic alliance, and co-development deals from his time at LG Life Sciences, Ltd. Mr. Suk currently owns BioCelsus International Inc., which has a consulting agreement with Abpro to provide business development and funding-related services.

Eugene Chan, Co-Founder, Chairman & Co-Founder

Eugene Chan co-founded Abpro in 2007 with his brother, Ian Chan. He also co-founded US Genomics (later known as PathoGenetix), a high-speed gene sequencing company, in 1998, where he served as Chairman and CEO until 2003. US Genomics successfully raised $25 million in venture capital. Dr. Chan currently manages rHEALTH, a digital health company, and operates the DNA Medicine Institute, a medical innovation laboratory. He holds over 60 patents and numerous publications in biochemistry, diagnostics, and nucleic acid analysis.

Ian Chan, Co-Founder

Ian Chan co-founded Abpro in 2007 with his brother, Eugene Chan. He previously served as Abpro's Chief Executive Officer from 2004 to 2018, and again from January 2020 until March 2025. He also held the role of Chairman of Abpro's board of directors from 2004 to January 2020. Prior to Abpro, he co-founded US Genomics (later PathoGenetix) in 1998, where he served as CFO and Vice President of Corporate Development until 2003. Mr. Chan also has prior experience with Morgan Stanley.

Robert J. Markelewicz, Jr., Chief Medical Officer

Robert J. Markelewicz, Jr. has served as Abpro's Chief Medical Officer since June 2018. Before joining Abpro, he was a Senior Medical Director at Celgene Corporation, a pharmaceutical company, from December 2014 to July 2018. Prior to that, he was a Medical Director at Parexel International Corporation, a biopharmaceutical services provider, from December 2012 to December 2014. Dr. Markelewicz's employment with Abpro is set to terminate on November 30, 2025.

A current Chief Financial Officer for Abpro is not publicly disclosed as of November 7, 2025, following the resignation of Shahraab Ahmad as CFO, which was effective November 22, 2024.

AI Analysis | Feedback

The key risks for Abpro (ABP) are primarily centered around its financial viability, regulatory compliance, and a critical licensing agreement:

1. Going Concern and Financial Instability: Abpro faces significant challenges regarding its financial stability and operational continuity. The company has a history of substantial operating losses and accumulated deficits, with management expressing considerable doubt about its ability to continue as a going concern due to ongoing losses and a lack of committed financing. Abpro's current cash balance is insufficient for long-term operations, making its dependence on future capital funding a critical concern.
2. Nasdaq Delisting Risk: Abpro has received notification from Nasdaq concerning non-compliance with listing requirements, including maintaining a minimum bid price and market capitalization. Failure to address these deficiencies could lead to the delisting of its shares, which would severely impact the company's ability to raise capital and the liquidity of its stock.
3. Breach of License Agreement with AstraZeneca: Abpro is currently in breach of the terms of its license agreement with AstraZeneca (formerly MedImmune Limited) for intellectual property rights related to ABP-201. This represents a significant legal and operational risk, as the company could potentially lose the rights to this product candidate.

AI Analysis | Feedback

The rapid advancement and proliferation of novel therapeutic modalities, including increasingly sophisticated multispecific antibodies developed by numerous larger pharmaceutical and biotechnology companies, and advanced cell therapies (such as CAR-T and CAR-NK cells), for the treatment of oncology and autoimmune diseases. These modalities directly compete with and potentially offer advantages over Abpro's current pipeline and single-domain antibody platform, raising the competitive bar for clinical efficacy, safety, and market access in a highly competitive therapeutic landscape.

AI Analysis | Feedback

AI Analysis | Feedback

Abpro (ABP) has several anticipated drivers for future revenue growth over the next two to three years, primarily centered on the advancement of its proprietary antibody therapeutics pipeline and strategic collaborations.

1. Advancement and Commercialization of ABP-102: Abpro's lead product candidate, ABP-102, a bispecific antibody for HER2+ solid tumors, is being developed and commercialized through a worldwide strategic partnership with Celltrion Inc.. Celltrion funds all development expenses for ABP-102, with Abpro retaining significant commercial and economic rights. A Phase 1/2 clinical trial for ABP-102 is expected to commence in the first half of 2026, which could trigger milestone payments and pave the way for future commercial revenue.
2. Advancement and Commercialization of ABP-201: ABP-201 is an ophthalmology candidate targeting Wet AMD and diabetic macular edema. Clinical trials for ABP-201 are projected to begin in the second half of 2025. This program is also part of a territorial partnership with Abpro Bio for Asian markets, with Abpro retaining rights in other regions, potentially leading to milestone payments and eventual sales.
3. Advancement and Commercialization of ABP-150: ABP-150 is a bispecific antibody designed for gastric cancers, with clinical trials anticipated to start in the first half of 2027. Abpro has a collaboration agreement with Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd (NJCTTQ) for exclusive commercialization rights in China and Thailand, while Abpro maintains rights in the rest of the world, offering another potential stream of revenue through development milestones and future sales.
4. Strategic Partnerships and Broader Pipeline Expansion: Beyond its lead candidates, Abpro leverages its proprietary DiversImmune® and MultiMab™ antibody discovery and engineering platforms to develop a broader pipeline of next-generation antibody therapies, including additional oncology, ophthalmology, and infectious disease indications. The company actively seeks and engages in strategic partnerships, which provide funding for development expenses, technology validation, and potential milestone payments and royalties as pipeline assets progress through clinical development and regulatory approvals.

AI Analysis | Feedback

Share Issuance

• Abpro completed a private investment in public equity (PIPE) offering, issuing 1,122,467 shares of Common Stock and 2,244,934 Incentive Shares, which raised $7.0 million in gross proceeds in late 2024/early 2025.
• The company raised an additional $2.76 million through convertible note financing with Yorkville in December 2024.
• Abpro entered into a Standby Equity Purchase Agreement (SEPA) with Yorkville to potentially issue up to $50 million in shares of common stock. Stockholders approved the issuance of shares representing over 20% of the company's common stock to Yorkville under this agreement in April 2025.

Inbound Investments

• Celltrion, a South Korean biotechnology company, has partnered with Abpro in an exclusive collaboration and is funding all development expenses for Abpro's lead antibody program ABP-102.
• A private investment in public equity (PIPE) offering in connection with its business combination generated $7.0 million in gross proceeds for the company in late 2024/early 2025.
• Abpro secured $2.76 million through convertible note financing with Yorkville in December 2024.

Capital Expenditures

• Abpro Holdings reported capital expenditures of $0.07 million in 2022 and $0.05 million in 2023.
• The company's primary focus for capital allocation is on advancing its pipeline of next-generation antibody therapies, with clinical trials for ABP-102 and ABP-201 anticipated in 2026.
• Debt financing and preferred equity financing agreements may include restrictive covenants that limit Abpro's ability to make capital expenditures.